⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932071 | 0.67 | — | — | |
| SCHEMBL8841030 | 0.59 | — | — | |
| SCHEMBL34508 | 0.59 | — | — | |
| SCHEMBL20745 | 0.59 | — | — | |
| SCHEMBL28820 | 0.59 | — | — | |
| SCHEMBL323342 | 0.59 | — | — | |
| SCHEMBL28819 | 0.59 | — | — | |
| SCHEMBL8841031 | 0.59 | — | — | |
| SCHEMBL27710 | 0.56 | — | — | |
| SCHEMBL195489 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220095-A1 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H LUNDBECK AS (DK) | 2022-07-14 | — | — | US | disclosed |
| US-20220204489-A1 | ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H LUNDBECK AS (DK) | 2022-06-30 | — | — | US | disclosed |
| CN-113710318-A | Arylsulfonyl thiophenecarboxamides and arylsulfonyl furancarboxamides as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113692405-A | Derivatives of N- ((heteroaryl) methyl) -1-tosyl-1H-pyrazole-3-carboxamide as KV3 potassium channel activators for the treatment of neurological or psychiatric disorders | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3873891-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS | H. Lundbeck A/S (DK) | 2021-09-08 | — | — | EP | disclosed |
| CN-113056461-A | Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2020216920-A1 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216919-A1 | ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-10-29 | — | — | WO | disclosed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
| CN-105829454-B | Dye composition | 默克专利股份有限公司 | 2018-11-09 | — | — | CN | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |